US OptionsDetailed Quotes
GPCR240719P50000
- 8.00
- +2.70+50.94%
15min DelayClose Jul 17 15:59 ET
8.00High8.00Low
8.00Open5.30Pre Close10 Volume59 Open Interest50.00Strike Price8.00KTurnover259.48%IV-9.55%PremiumJul 19, 2024Expiry Date11.66Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9045Delta0.0235Gamma3.21Leverage Ratio-0.2480Theta-0.0021Rho-2.90Eff Leverage0.0047Vega
Structure Therapeutics Stock Discussion
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US)$ $Novo-Nordisk A/S(NVO.US)$ $Structure Therapeutics(GPCR.US)$ $Viking Therapeutics(VKTX.US)$ $Lipocine(LPCN.US)$
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US)$ Orforglipron and $Structure Therapeutics(GPCR.US)$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
On fire
Therapeutics Inc, a leading biopharmaceutical company, public offer at $31.90 per share USD for the acquisition of 17 million shares. The offer is subject to closing on June 7, 2024. This move reflects the company's commitment to expanding its market presence and fostering financial growth. Investors and stakeholders are urged to capitalize on this lucrative opportunity. Therapeutics Inc antici...
$Iovance Biotherapeutics(IOVA.US)$ Phase 2
$Supernus Pharmaceuticals(SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$ Phase 2a
$MorphoSys(MOR.US)$ Phase 2
$Nuvation Bio(NUVB.US)$ Phase 2
$ALX Oncology(ALXO.US)$ Phase 2
$BioXcel Therapeutics(BTAI.US)$ Phase 2
$Purple Biotech(PPBT.US)$ Phase 2
$Arcus Biosciences(RCUS.US)$ Phase 2
$Medicenna Therapeutics(MDNAF.US)$ Phase 2b
$Affimed NV(AFMD.US)$ Phase 2
$Barinthus Biotherapeutics(BRNS.US)$ Phase 2b...
No comment yet